Shihong Peng

639 total citations
16 papers, 395 citations indexed

About

Shihong Peng is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Shihong Peng has authored 16 papers receiving a total of 395 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Shihong Peng's work include Ubiquitin and proteasome pathways (3 papers), Prostate Cancer Treatment and Research (3 papers) and Cancer Mechanisms and Therapy (2 papers). Shihong Peng is often cited by papers focused on Ubiquitin and proteasome pathways (3 papers), Prostate Cancer Treatment and Research (3 papers) and Cancer Mechanisms and Therapy (2 papers). Shihong Peng collaborates with scholars based in China, United States and United Kingdom. Shihong Peng's co-authors include Zhengfang Yi, Mingyao Liu, Yundong He, Wen‐Wei Qiu, Meichun Hu, Xiaonan Cong, Min Qin, Yuan He, Chen Huang and Liguo Wang and has published in prestigious journals such as Nature Communications, Oncogene and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Shihong Peng

16 papers receiving 393 citations

Peers

Countries citing papers authored by Shihong Peng

Since Specialization

Citations

This map shows the geographic impact of Shihong Peng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shihong Peng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shihong Peng more than expected).

Fields of papers citing papers by Shihong Peng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shihong Peng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shihong Peng. The network helps show where Shihong Peng may publish in the future.

Co-authorship network of co-authors of Shihong Peng

This figure shows the co-authorship network connecting the top 25 collaborators of Shihong Peng. A scholar is included among the top collaborators of Shihong Peng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shihong Peng. Shihong Peng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Remodeling the immune microenvironment for gastric cancer therapy through antagonism of prostaglandin E2 receptor 4 2023 ·Genes & Diseases ·Mengmeng Guo, Pan Hu, (unknown), Kefu Tang, (unknown), (unknown), Yundong He, (unknown), Weiqiang Lü, Huirong Liu, Mingyao Liu, Zhengfang Yi, Shihong Peng	2
2	A small molecule BCL6 inhibitor as chemosensitizers in acute myeloid leukemia 2023 ·Biomedicine & Pharmacotherapy ·Zhang Li, Min Wu, Weikai Guo, Shuangshuang Zhu, Shen Li, (unknown), Yan Li, (unknown), (unknown), Chen Huang, Mingyao Liu, Shihong Peng, Yihua Chen, Zhengfang Yi	6
3	Regression of Castration-Resistant Prostate Cancer by a Novel Compound HG122 2021 ·Frontiers in Oncology ·Xiaonan Cong, Yundong He, Haigang Wu, (unknown), Yongrui Liu, (unknown), Mingyao Liu, Zhengfang Yi, Jianghua Zheng, Shihong Peng, Tao Ding	5
4	Targeting STAT3 by a small molecule suppresses pancreatic cancer progression 2021 ·Oncogene ·(unknown), (unknown), (unknown), Xuan Yin, Jie Wang, (unknown), Ying Miao, Shihong Peng, Shifen Xu, Mingyao Liu, Wen‐Wei Qiu, Zhengfang Yi	59
5	Novel Long Non-coding RNA lncAMPC Promotes Metastasis and Immunosuppression in Prostate Cancer by Stimulating LIF/LIFR Expression 2020 ·Molecular Therapy ·Wei Zhang, Xiaolei Shi, Rui Chen, Yasheng Zhu, Shihong Peng, Yifan Chang, (unknown), Guangan Xiao, Ziyu Fang, Yaoming Li, (unknown), Zhao Lin, Guang Liu, Yinghao Sun, Shancheng Ren	27
6	Regression of castration-resistant prostate cancer by a novel compound QW07 targeting androgen receptor N-terminal domain 2020 ·Cell Biology and Toxicology ·Shihong Peng, Jie Wang, Chen Huang, Pan Hu, Xiaolong He, Yundong He, (unknown), Wenshu Tang, (unknown), Yingying Wang, (unknown), Dandan Guo, Shancheng Ren, Mingyao Liu, Wen‐Wei Qiu, Zhengfang Yi	15
7	Determining the Drug-Like Properties of Ailanthone, a Novel Chinese Medicine Monomer with Anti-CRPC Activity 2020 ·Planta Medica ·Pan Hu, Dandan Guo, (unknown), Chen Huang, (unknown), (unknown), Shifen Xu, Zhengfang Yi, Shihong Peng, Mingyao Liu	3
8	A novel BMI-1 inhibitor QW24 for the treatment of stem-like colorectal cancer 2019 ·Journal of Experimental & Clinical Cancer Research ·Jinhua Wang, (unknown), Yingying Wang, Yundong He, Liting Wang, Shihong Peng, (unknown), (unknown), Xiaotao Li, Wen‐Wei Qiu, Zhengfang Yi, Mingyao Liu	21
9	A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling 2017 ·Science China Life Sciences ·Yongrui Liu, Yuan He, Feifei Yang, Xiaonan Cong, Jinhua Wang, Shihong Peng, Dan Gao, Weifang Wang, Liping Lan, (unknown), Mingyao Liu, Yihua Chen, Zhengfang Yi	10
10	Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer 2016 ·Nature Communications ·Yundong He, Shihong Peng, Jinhua Wang, Chen Huang, Xiaonan Cong, Ang Chen, Meichun Hu, Min Qin, Haigang Wu, (unknown), Liguo Wang, Xin Wang, Zhengfang Yi, Mingyao Liu	79
11	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity 2016 ·European Journal of Medicinal Chemistry ·Yingying Wang, Yuan He, (unknown), Shihong Peng, Xiaolong He, Jinhua Wang, Fang Lv, Yun Hao, Mingyao Liu, Zhengfang Yi, Wen‐Wei Qiu	16
12	Synthesis and biological evaluation of D-ring fused 1,2,3-thiadiazole dehydroepiandrosterone derivatives as antitumor agents 2016 ·European Journal of Medicinal Chemistry ·(unknown), Shihong Peng, (unknown), Chen Huang, Yuan He, Wei Gao, Fang Lv, (unknown), Yan Wang, Jia Xie, Mingyao Liu, Zhengfang Yi, Wen‐Wei Qiu	28
13	LG308, a Novel Synthetic Compound with Antimicrotubule Activity in Prostate Cancer Cells, Exerts Effective Antitumor Activity 2015 ·Journal of Pharmacology and Experimental Therapeutics ·Min Qin, Shihong Peng, Ning Liu, Meichun Hu, Yundong He, Guoliang Li, Chen Huang, Yuan He, Ang Chen, Xin Wang, Mingyao Liu, Yihua Chen, Zhengfang Yi	5
14	A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities 2015 ·Organic & Biomolecular Chemistry ·Feifei Yang, Shihong Peng, Yunqi Li, (unknown), (unknown), Jing Wu, (unknown), Mingyao Liu, Zhengfang Yi, Yihua Chen	16
15	Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer 2015 ·Oncotarget ·Meichun Hu, Shihong Peng, Yundong He, Min Qin, Xiaonan Cong, (unknown), Mingyao Liu, Zhengfang Yi	68
16	Synthesis of Novel Heterocyclic Ring‐Fused 18β‐Glycyrrhetinic Acid Derivatives with Antitumor and Antimetastatic Activity 2014 ·Chemical Biology & Drug Design ·Cheng Gao, Fujun Dai, (unknown), Shihong Peng, Yuan He, Xue Wang, Zhengfang Yi, Wen‐Wei Qiu	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact